Summary: In adults with obesity participating in a double-blind clinical pharmacology study, once-daily oral semaglutide (dose-escalated to 50 mg over…
Browsing: Semaglutide
Summary: In adults with obesity-related heart failure with preserved ejection fraction (HFpEF), left ventricular ejection fraction ≥45%, and BMI ≥30…
Summary: In patients with obesity-related heart failure with preserved ejection fraction (HFpEF), including those enrolled in the STEP-HFpEF and STEP-HFpEF…
Brief Results In Adults with chronic kidney disease (eGFR ≥25 ml min-1 1.73 m-2 and UACR ≥30 and <3,500 mg…
In patients with type 2 diabetes (T2D), once-weekly semaglutide significantly increased the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to non-exposure, doubling the five-year hazard ratio (HR), though it was associated with improved glycaemic control and other cardiometabolic benefits.
Summary: In healthy Chinese adults, once-daily oral semaglutide (3 mg escalating to 14 mg over 12 weeks) significantly reduced body…
Summary: In adults with overweight or obesity participating in the STEP 1-4 Phase 3a trials over 68 weeks, once-weekly semaglutide…
Summary: In adults with preexisting cardiovascular disease, overweight or obesity, and no prior diagnosis of diabetes, semaglutide (GLP-1 receptor agonist)…
Summary: In patients with type 2 diabetes and chronic kidney disease (CKD), weekly semaglutide 1.0 mg for a median of…
PICO Description Population Patients with obesity-related heart failure with preserved ejection fraction (HFpEF), enrolled in the STEP-HFpEF program, involving 1,145…